Nathan Fuller, Ph.D.

Nathan Fuller, Ph.D., is Vice President, Chemistry at Rectify.  He brings to the team over 18 years of experience in drug discovery and medicinal chemistry.  Prior to joining Rectify, Nathan was Senior Director of Chemistry at Rodin Therapeutics, progressing complex-selective HDAC inhibitors to the clinic for treatment of synaptic pathology in neurologic disorders.  Rodin Therapeutics was acquired in 2019 by Alkermes.  Previously, Nathan worked at AstraZeneca on fragment-based lead generation for a range of targets across multiple therapeutic areas.  He also worked at Satori Pharmaceuticals on gamma-secretase modulators for Alzheimer’s disease, and at Wyeth Research in the inflammation department.  Nathan is a co-author/co-inventor on more than 35 publications and patents.  He conducted post-doctoral research with Professor Stephen F. Martin at the University of Texas at Austin, received his Ph.D. in Organic Chemistry from the University of North Carolina at Chapel Hill with Professor James P. Morken, and a B.S. degree in chemistry from the University of Massachusetts at Amherst.